Last reviewed · How we verify
NCT04941144
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
trial testing COVID-19 Vaccine in Coronavirus Disease (COVID-19) in 8,538 participants. Completed in 28 April 2023.
28 April 2023
Quick facts
| Lead sponsor | ModernaTX, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8,538 |
| Start date | 22 December 2021 |
| Primary completion | 28 April 2023 |
| Estimated completion | 28 April 2023 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- COVID-19 Vaccine (COVID-19 Vaccine) — full drug profile →
Conditions studied
- Coronavirus Disease (COVID-19) — all drugs for Coronavirus Disease (COVID-19) →
Sponsor
ModernaTX, Inc. — full company profile →
Who can join
Eligibility, any sex, with Coronavirus Disease (COVID-19). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a long-term follow-up survey of Japanese people after their second vaccination with the Moderna COVID-19 vaccine. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for long-term side effects of the COVID-19 vaccine. This will be from 28 days to 12 months after the second vaccination of the COVID-19 vaccine. The number of visits to the clinic will depend on the clinic's standard practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04941144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COVID-19 Vaccine
Trials testing the same drug.
- NCT06864143 — A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in A · Phase 2 · completed
- NCT06683352 — A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People · Phase 1, PHASE2 · completed
- NCT06163677 — A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza. · withdrawn
- NCT06178991 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against CO · Phase 3 · completed
- NCT06097273 — A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age · Phase 3 · completed
Other recruiting trials for Coronavirus Disease (COVID-19)
Currently open trials in the same condition.
- NCT06667700 — A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are Hi · Phase 3 · recruiting
Other ModernaTX, Inc. trials
Trials by the same sponsor.
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
- NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
- NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04941144 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing